BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kammarabutr J, Mahalapbutr P, Nutho B, Kungwan N, Rungrotmongkol T. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation. J Mol Graph Model 2019;89:122-30. [PMID: 30884449 DOI: 10.1016/j.jmgm.2019.03.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Boonma T, Nutho B, Darai N, Rungrotmongkol T, Nunthaboot N. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study. J Biomol Struct Dyn 2021;:1-12. [PMID: 33430709 DOI: 10.1080/07391102.2020.1869587] [Reference Citation Analysis]
2 Nutho B, Mahalapbutr P, Hengphasatporn K, Pattaranggoon NC, Simanon N, Shigeta Y, Hannongbua S, Rungrotmongkol T. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms. Biochemistry 2020;59:1769-79. [PMID: 32293875 DOI: 10.1021/acs.biochem.0c00160] [Cited by in Crossref: 96] [Cited by in F6Publishing: 81] [Article Influence: 48.0] [Reference Citation Analysis]
3 Mahalapbutr P, Lee VS, Rungrotmongkol T. Binding Hotspot and Activation Mechanism of Maltitol and Lactitol toward the Human Sweet Taste Receptor. J Agric Food Chem 2020;68:7974-83. [PMID: 32551626 DOI: 10.1021/acs.jafc.0c02580] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Aiebchun T, Mahalapbutr P, Auepattanapong A, Khaikate O, Seetaha S, Tabtimmai L, Kuhakarn C, Choowongkomon K, Rungrotmongkol T. Identification of Vinyl Sulfone Derivatives as EGFR Tyrosine Kinase Inhibitor: In Vitro and In Silico Studies. Molecules 2021;26:2211. [PMID: 33921332 DOI: 10.3390/molecules26082211] [Reference Citation Analysis]
5 Thirunavukkarasu MK, Suriya U, Rungrotmongkol T, Karuppasamy R. In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach. Pharmaceutics 2021;14:59. [PMID: 35056955 DOI: 10.3390/pharmaceutics14010059] [Reference Citation Analysis]
6 Yoshino R, Yasuo N, Sekijima M. Molecular Dynamics Simulation reveals the mechanism by which the Influenza Cap-dependent Endonuclease acquires resistance against Baloxavir marboxil. Sci Rep 2019;9:17464. [PMID: 31767949 DOI: 10.1038/s41598-019-53945-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
7 Elsässer B, Goettig P. Mechanisms of Proteolytic Enzymes and Their Inhibition in QM/MM Studies. Int J Mol Sci 2021;22:3232. [PMID: 33810118 DOI: 10.3390/ijms22063232] [Reference Citation Analysis]
8 Mahalapbutr P, Sangkhawasi M, Kammarabutr J, Chamni S, Rungrotmongkol T. Rosmarinic Acid as a Potent Influenza Neuraminidase Inhibitor: <i>In Vitro</i> and <i>In Silico</i> Study. Curr Top Med Chem 2020;20:2046-55. [PMID: 31738149 DOI: 10.2174/1568026619666191118110155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
9 Sanachai K, Mahalapbutr P, Choowongkomon K, Poo-Arporn RP, Wolschann P, Rungrotmongkol T. Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases. ACS Omega 2020;5:369-77. [PMID: 31956784 DOI: 10.1021/acsomega.9b02800] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Boonma T, Nutho B, Rungrotmongkol T, Nunthaboot N. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective. Comput Biol Chem 2019;83:107154. [PMID: 31751885 DOI: 10.1016/j.compbiolchem.2019.107154] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sanachai K, Mahalapbutr P, Sanghiran Lee V, Rungrotmongkol T, Hannongbua S. In Silico Elucidation of Potent Inhibitors and Rational Drug Design against SARS-CoV-2 Papain-like Protease. J Phys Chem B 2021;125:13644-56. [PMID: 34904832 DOI: 10.1021/acs.jpcb.1c07060] [Reference Citation Analysis]
12 Nutho B, Pengthaisong S, Tankrathok A, Lee VS, Ketudat Cairns JR, Rungrotmongkol T, Hannongbua S. Structural Basis of Specific Glucoimidazole and Mannoimidazole Binding by Os3BGlu7. Biomolecules 2020;10:E907. [PMID: 32549280 DOI: 10.3390/biom10060907] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Kammarabutr J, Mahalapbutr P, Okumura H, Wolschann P, Rungrotmongkol T. Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase. J Biomol Struct Dyn 2021;39:2502-11. [PMID: 32308149 DOI: 10.1080/07391102.2020.1751715] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Somboon T, Mahalapbutr P, Sanachai K, Maitarad P, Lee VS, Hannongbua S, Rungrotmongkol T. Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease. J Mol Liq 2021;322:114999. [PMID: 33518853 DOI: 10.1016/j.molliq.2020.114999] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]